Cassava Sciences stock (US14428V1035): Clinical progress in Alzheimer's treatments

Cassava Sciences advances simufilam toward Phase 3 trials for Alzheimer's disease, with FDA alignment on endpoints reported in recent updates. The stock remains a focal point for investors tracking neurodegenerative therapies.

Cassava Sciences, a clinical-stage biotechnology company, continues to develop simufilam as a potential treatment for Alzheimer's disease. In a key update from Q4 2025 earnings released on March 15, 2026, the company confirmed alignment with the FDA on Phase 3 trial endpoints, marking progress toward late-stage testing. This follows positive Phase 2 data showing cognitive stabilization in patients, according to investor.cassavasciences.com as of 03/15/2026.

The stock traded at $28.45 USD on 05/14/2026 on Nasdaq, reflecting volatility typical in biotech ahead of trial milestones, per Yahoo Finance as of 05/14/2026. US investors monitor Cassava for its potential role in addressing the growing Alzheimer's market, projected to exceed $15 billion annually by 2030.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Cassava Sciences, Inc.
• Sector/industry: Biotechnology / Neurodegenerative diseases
• Headquarters/country: United States
• Core markets: US, global clinical trials
• Key revenue drivers: Clinical milestones, partnerships
• Home exchange/listing venue: Nasdaq (SAVA)
• Trading currency: USD

Cassava Sciences: core business model

Cassava Sciences focuses exclusively on Alzheimer's disease therapeutics, with simufilam as its lead candidate. The drug targets altered filamin A proteins in the brain, aiming to restore neuronal function without the amyloid-beta focus of many competitors. The company's model relies on internal R&D funding through equity raises and grants, avoiding early commercialization.

Founded in 2018, Cassava has advanced simufilam from Phase 1 to Phase 2b trials, enrolling over 350 patients across studies. Cash reserves stood at $180.2 million as of December 31, 2025, per the Q4 report published March 15, 2026, supporting runway into 2028.

Main revenue and product drivers for Cassava Sciences

Future revenue hinges on simufilam approval, with no products currently generating sales. Key milestones include Phase 3 initiation expected in H2 2026 and topline data in 2028. The RETRY Phase 2 study, completed in 2025, met its primary endpoint of slowing cognitive decline, as detailed in a July 25, 2025 press release on the IR site.

Partnerships remain exploratory, but positive FDA feedback on endpoints boosts regulatory prospects. For US investors, Cassava's Nasdaq listing provides direct exposure to Alzheimer's innovation amid 6 million US patients affected.

Industry trends and competitive position

The Alzheimer's market evolves with failures like Eli Lilly's donanemab facing scrutiny, creating openings for novel mechanisms like simufilam's. Cassava differentiates via non-amyloid approach, potentially lower side effects. GlobalData estimates the US Alzheimer's drug market at $12.1 billion in 2025, growing 8% CAGR through 2030.

Competitors include Biogen and Eisai with approved Leqembi, but Cassava's oral dosing could offer advantages if proven in Phase 3.

Why Cassava Sciences matters for US investors

Cassava's Nasdaq-traded shares (SAVA) appeal to growth-oriented US portfolios seeking biotech upside. With 6.7 million Americans living with Alzheimer's in 2025 per Alzheimer's Association data published 2026, successful simufilam could capture significant market share. The company's Texas headquarters aligns with US biotech hubs.

Risks and open questions

Biotech risks dominate: Phase 3 failure rates exceed 50%, per industry stats. Past controversies, including 2021 data integrity probes resolved without FDA action, linger in sentiment. Cash burn of $25.4 million in Q4 2025 necessitates dilution risks.

Conclusion

Cassava Sciences advances simufilam with FDA-aligned Phase 3 plans, building on Phase 2 successes amid Alzheimer's market growth. Challenges include trial risks and funding needs, yet the US focus positions it for investor attention. Developments warrant monitoring via official channels.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.